P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients

Guardat en:
Dades bibliogràfiques
Autors principals: Sylvan, S Eketorp, Lundin, J, Ipek, M, Palma, M, Karlsson, C, Hansson, L
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Poster Presentation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4072199/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2051-1426-2-S2-P18
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars